Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease
about
Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growthMolecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vectorStimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptorCD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survivalT cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factorsTumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activationHuman embryonal epithelial cells of the developing small intestinal crypts can express the Hodgkin-cell associated antigen Ki-1 (CD30) in spontaneous abortions during the first trimester of gestationBer-H2 (CD30) immunohistochemical staining of human fetal tissuesCD30: from basic research to cancer therapyPleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) familyCD27-CD70 interaction: unravelling its implication in normal and neoplastic B-cell growthCD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteinsTumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activationThe molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosisThiols decrease cytokine levels and down-regulate the expression of CD30 on human allergen-specific T helper (Th) 0 and Th2 cellsAn anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion.Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin.CD30 ligand (CD30L)-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cells proliferation.Eosinophil survival and apoptosis in health and disease.Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.TNF alpha and the TNF receptor superfamily: structure-function relationship(s).Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologueAnaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology.Ki-1/57 interacts with RACK1 and is a substrate for the phosphorylation by phorbol 12-myristate 13-acetate-activated protein kinase C.The role of CD30 in atopic disease.Anaplastic large cell lymphoma: pathological, molecular and clinical features.Translocations involving anaplastic lymphoma kinase (ALK).Hodgkin's lymphoma: the pathologist's viewpointFrequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases.The significance of immunohistochemistry in the diagnosis and therapy of neoplasms.CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal typeNew strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapiesHypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma.Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.TRAF2 recruitment via T61 in CD30 drives NFκB activation and enhances hESC survival and proliferation.Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicityMolecular genetic study of novel biomarkers for early diagnosis of oral squamous cell carcinomaExpression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
P2860
Q22003914-E8B44782-88ED-4563-B754-D4A0E32C8FB1Q24312084-BAC91E5A-A17C-48E7-B353-806793E07EECQ24316194-C4966763-3D8C-44DD-BAD4-02B5A03DCC30Q24597543-D6B00646-59E3-4909-8EB6-1093A9060B37Q24605401-1875BE71-2204-453D-BDAE-C33FC13E938DQ24678367-BB8627F5-A73A-4850-AB79-5079BA524EB4Q24679579-45452E19-02E7-4B21-8AC6-0CDAA0858D6FQ24796291-468592D0-2D1C-401D-A954-6D5B25F8B020Q24817157-743EB358-7130-49BD-AECB-46DBB7AAA088Q26859079-13C03142-4548-4E59-B089-006C115BDFB9Q28208696-9AE7B660-1C07-4595-848A-2356DE6F59CAQ28274504-4363CB45-0692-437E-8E9A-0827C83A6DC0Q28281794-86BD63CB-0FB9-4C10-87FC-044708210E5FQ28301504-94304E5F-4B3F-4EFC-BD5D-0A75057E4F84Q28306517-48925A74-F06A-4455-887D-5F6BAA66561DQ28362305-98F56629-E6DB-4C14-B804-DA5AC3D9E28EQ30720500-D7456CF0-005E-42EC-BB9A-155570744305Q31147001-552CCB88-8EE4-41E2-93F2-1C02BF5308A3Q31915221-8046E715-BBE5-4FA6-B6F9-EA7416A12692Q33747241-E4CC05DC-3609-4740-98E2-A5A9CF8257B9Q33758139-FB806149-B25E-446E-AA20-EF896CA84FFBQ33841251-2703E0E2-B34C-48F2-AC65-43F33BD411AAQ33909217-7E92C6BE-07CB-4B1D-A9FB-B81C3B50DA35Q34032643-A3C69116-382A-4079-BC8E-1669E105AF60Q34194246-D419BBDE-E27E-4C60-AD57-791D3D7EAF8EQ34286845-642DDBCA-C5A3-45DF-A3ED-5DE69DD2C08EQ34291177-E31FD4BC-466A-4466-A951-473C86C6614AQ34374218-7F8D0E81-9A6D-4F68-BE8F-99A5CEEB2082Q34405439-8DB00C49-0D51-49BD-808B-41083E1B7ED2Q34564836-A4954835-65E8-48B4-88BD-095041844CADQ34595732-A9E0F096-DF70-41AD-B22E-35C1538AF85DQ34602545-EF023E31-C864-4550-A61A-1FA2092919C6Q34650606-6E13055C-0A2B-46CD-B218-22AC44237750Q34683488-52F17B10-CCC4-4B17-8DF1-351334537A48Q34707404-1F033116-10DC-4014-AD4A-CD0C1C3C757AQ35051886-79D43259-4842-4B93-9E4B-1A96D6FA7F79Q35125212-C45BFCDC-AC31-468E-AC9E-25CDAAABD9E8Q35326190-EBB9A336-1214-4F59-8ED4-955585F661A0Q35374065-EAB31819-03F6-4AF2-B6C2-1C6539A08E5DQ35774239-5BBDDC81-CBE8-4843-9550-EB8A2398CD1E
P2860
Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease
description
1992 nî lūn-bûn
@nan
1992 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@ast
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@en
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@en-gb
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@nl
type
label
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@ast
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@en
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@en-gb
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@nl
prefLabel
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@ast
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@en
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@en-gb
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@nl
P2093
P1433
P1476
Molecular cloning and expressi ...... teristic for Hodgkin's disease
@en
P2093
P356
10.1016/0092-8674(92)90180-K
P407
P577
1992-02-07T00:00:00Z